Skip to main content
Ruben Niesvizky, MD, Hematology, New York, NY

RubenNiesvizkyMD

Hematology New York, NY

Hematologic Oncology

Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Niesvizky

Dr. Ruben Niesvizky is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from Universidad Nacional Autonoma de Mexico and has been in practice 32 years. Dr. Niesvizky accepts several types of health insurance, listed below. He is one of 64 doctors at New York-Presbyterian Hospital and one of 25 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Hematology. He also speaks multiple languages, including Hebrew and Spanish. He has more than 100 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1990 - 1994
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1988 - 1990
  • Universidad Nacional Autonoma de Mexico
    Universidad Nacional Autonoma de MexicoClass of 1985

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 1993 - Present
  • NY State Medical License
    NY State Medical License 1994 - 2025

Awards, Honors, & Recognition

  • Top doctors Newsweek, 2015
  • New York Magazine: Top Doctors Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Carfilzomib vs Bortezomib in Patients with Multiple Myeloma and Renal Failure: A Subgroup Analysis of ENDEAVOR  
    Ruben Niesvizky, David Siegel, Ralph Boccia, Blood

Abstracts/Posters

  • Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
    Ruben Niesvizky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis
    Ruben Niesvizky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not ...
    Ruben Niesvizky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Blood Test May Guide Multiple Myeloma Immunotherapy Use
    Blood Test May Guide Multiple Myeloma Immunotherapy UseJuly 27th, 2024
  • Routine Blood Test May Guide Use of Multiple Myeloma Immunotherapy
    Routine Blood Test May Guide Use of Multiple Myeloma ImmunotherapyJuly 24th, 2024
  • A Day in the Life of a Nurse Who Works 10-Hour Shifts in an NYC Cancer Unit Keeping Patients Comfortable in the Midst of a National Drug Shortage
    A Day in the Life of a Nurse Who Works 10-Hour Shifts in an NYC Cancer Unit Keeping Patients Comfortable in the Midst of a National Drug ShortageAugust 21st, 2019
  • Join now to see all

Professional Memberships

Other Languages

  • Hebrew, Spanish

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    HIP of New York - Select PPO
    MagnaCare PPO
    MVP Healthcare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment